Welcome to Lanthio Pharma
About Lanthio Pharma
Lanthio Pharma is a biopharmaceutical company focused on discovering and developing Lantipeptides, a new class of peptides with high target selectivity and improved "drug-like" properties.
PEPTIDES ARE BECOMING INCREASINGLY POPULAR AS THERAPEUTIC DRUGS
Peptide therapeutics are an increasingly important class of drugs. As natural ligands to many targets, they can combine agonistic or antagonistic activity with low toxicity risk. Importantly they can be applied to targets, where small molecules or antibody-based drugs are not an option.
CREATING RECEPTOR SPECIFIC AGONISTIC PEPTIDES
A peptide can have different structural conformations. One conformation is often optimal for specific receptor binding. Lanthio Pharma's technology can be used to identify peptides which are selective for a specific target and to stabilize them in their optimal structural conformation for receptor binding. In this way we have already identified several selective and highly active agonistic peptides for GPCR targets. This increased target selectivity can open up exciting new therapeutic applications around known targets.
PROTECTION AGAINST DEGRADATION BY enzymes in plasma
A drawback of using peptides therapeutically can be their rapid degradation by peptidases in the body. Lanthio Pharma's technology not only stabilizes peptides in their optimal target binding conformation, the introduction of lanthionines also provides strong protection against peptidase degradation. As such, our lantipeptides typically have better "drug-like" properties, compared to natural linear peptides.
Lantipeptides occur in cheese
Nisin is a natural antibiotic lantipeptide, produced by Lactococcus bacteria in cheese. Nisin is also widely used as food preservative
News and events
- LANTHIO PHARMA ANNOUNCES TECHNOLOGY ALLIANCE WITH MORPHOSYS AG AND SECURES SERIES A FINANCING
- LANTHIO PHARMA RECEIVES GRANTs FROM samenwerkingsverband noord nederland and province of groningen
- LANTHIO PHARMA RECEIVES EUROSTARS GRANT
- Lanthio Pharma appoints Bart Wuurman as CEO.
- Lanthio Pharma licenses lanthionine-stabilized Angiotensin agonistic peptide drug to Tarix Pharmaceuticals.